The artificial intelligence (AI)-powered veterinary scribe, ScribbleVet, has achieved SOC 2 Type 2 compliance, a security certification considered the gold standard for data security and operational integrity.

 According to ScribbleVet, the goal in developing a secure system was to “help veterinary professionals care for animals without compromising on privacy or compliance."

The SOC 2 Type 2 audit looked at the systems, processes, and controls of ScribbleVet over a period of time to ensure the platform meets trust and security criteria. The SOC 2 Type 2 audit differs from SOC 2 Type 1, in that Type 1 only assesses a company’s security controls at 1 specific moment, whereas Type 2 evaluates these controls over the course of 3 to 12 months, typically. “ScribbleVet pushed to achieve the more comprehensive Type 2 in order to deliver a proven track record of keeping customer data safe,” the company wrote in a news release.

The SOC 2 Type 2 certification, developed by the American Institute of Certified Public Accountants but conducted by an independent third-party auditor, confirmed the veterinary scribe’s compliance with strict standards for data encryption, access controls, risk management, and system availability, according to ScribbleVet.

 In addition to passing the SOC 2 Type 2 audit, the company also completed an independent penetration test, or a simulated cyberattack, to identify potential weaknesses in a system.

"We recognize that veterinarians entrust us with highly sensitive information every day," Rohan Relan, CEO of ScribbleVet, said in a company release.

"That's why we deliberately implemented rigorous processes and controls. Achieving SOC 2 Type 2 compliance is a promise to our users that protecting their data with the highest level of security is nonnegotiable. Our goal is to help veterinary professionals care for animals without compromising privacy or compliance."

The AI-powered veterinary scribe, which can generate veterinary SOAP notes and draft client communications within minutes, was 

adopted by the University of Florida College of Veterinary Medicine

 (CVM) in Gainesville earlier this spring. According to ScribbleVet, the school was the first educational institution to adopt the AI platform systemwide.

"We chose ScribbleVet for its high accuracy and time-saving workflows, which allow clinicians to reclaim hours for patient care while seamlessly incorporating AI into student training,” Andrea Miller, assistant director of operations at the CVM, said in a news release.

 "This collaboration reflects our leadership in veterinary AI innovation, equipping future professionals with the tools to streamline workflows, advance diagnostics, and elevate standards of care.”

ScribbleVet achieves SOC 2 Type 2 compliance, validating data security in veterinary care. News release. ScribbleVet. May 5, 2025. Accessed May 8, 2025. https://www.prnewswire.com/news-releases/scribblevet-achieves-soc-2-type-2-compliance-validating-data-security-in-veterinary-care-302445276.html?tc=eml_cleartime

Coppock Crossley K. Veterinary college incorporates AI scribe into facilities and classrooms. 

https://www.dvm360.com/view/veterinary-college-incorporates-ai-scribe-into-facilities-and-classrooms

Articles

The certification validates that the platform meets trust and security criteria.

AI-powered veterinary scribe achieves SOC 2 Type 2 compliance

Kelly Cairns, DVM, MS, DACVIM (SAIM), discusses her on-demand lectures about polyarthritis and Cushing syndrome.

Endocrinology expert provides insights on 2 disorders

Kelly Cairns, DVM, MS, DACVIM (SAIM), vice president, medical excellence and education for Thrive Pet Healthcare, delivered a series of lectures on endocrinology topics at the 2025 Fetch dvm360 Conference in Charlotte, North Carolina. Some of these presentations are available to continuing education (CE) learners through the Fetch On-Demand platform.

In this video, Cairns discusses 2 of her on-demand lectures: “Polyarthritis” and “Is This Cushing's and Do I Care?” She explains what CE learners can gain from attending these lectures that take in-depth looks at polyarthritis and Cushing syndrome.

The following is a transcript of the video:

My session on polyarthritis is going to be a complete overview of this condition, which I feel like, in clinical practice as an internist, is kind of one of the great imposters. So we're going to unpack when you should be looking for it, when you think maybe you shouldn't even be looking for it. We're going to talk about how to test for it, all the different causes of it. We're also going to go through how anybody in clinical practice can easily perform great joint taps.

I love the session “Is this Cushings? And do I care?” So, here's the spoiler alert: you do care. You do care. But we're going to talk about why you should care, and what are the ways that you diagnose this condition and then determine if you should treat, because sometimes we don't, and what complications do we see with the condition that warrant monitoring and intervention if they exist.

 delivers expert-led veterinary continuing education on your schedule. With 

, you can access top-tier sessions anytime, anywhere—whether at home, in the clinic, or on the go. Ready to earn CE credits? Watch this session and more on 

Videos

Kelly Cairns, DVM, MS, DACVIM (SAIM), discusses her on-demand lectures about polyarthritis and Cushing syndrome. 

Aaron Shaw, OTR/L, CHT, CSCS, dives into the science of this sensation and offers advice on how to prevent it

Wellness Tip of the Week: Avoiding the “hangry” feeling

Last week, Shaw shared a 5-minute tip for handling stress during busy days. The full video is available to watch 

How does food and nutrition impact focus, mood, and stress levels? During this week’s wellness tip, Aaron Shaw, OTR/L, CHT, CSCS, healthspan coach and host of the 

podcast, discusses the importance of maintaining stable blood sugar levels to prevent the "hangry" feeling induced by blood sugar crashes. To avoid these crashes, Shaw shares some quick snacks veterinary professionals can graze on throughout the day.

Below is the video transcript, lightly edited for clarity:

 Hey, this is Aaron Shaw with another Wellness Tip of the Week. Today, I want to talk about something that affects your focus, your mood, and your stress level. We're talking about food and nutrition.

If you've ever found yourself necessarily skipping a lunch, powering through a lunch, or not being able to eat enough throughout the day, and then later on, you find yourself being a little snappy, a little foggy headed, [or] a little more stressed out than you feel like you should be, well, that's what we would expect because you probably have low blood sugar.

When your blood sugar crashes, there's this response with our body that releases cortisol and adrenaline. These are stress hormones. We know this. So that sensation of feeling "hangry," which is both hungry and angry—it's real. It's your body's full-system stress response to not having level blood sugar.

Let me give you 2 quick snacks you can have to keep at your desk [or] in the break room that you can grab and graze on throughout the day to keep your blood sugar a little more level. The first thing I love is hard-boiled eggs with some fruit. Hard-boiled eggs will give you some protein, and fruit—real fruit—is a great way to give you the protein, [which] will kind of level you out and [provide] a little bit of natural sugars.

The second thing that I really love to go to, again, is certainly a fruit with some nut butter. Same principles—it'll give you some protein and some natural sugars. When you graze on this throughout the day, you're giving your body a chance to have a maintained blood sugar level. You won't have those crashes, [crave] super sugary stuff, and then go back in the break room [where] you have donuts or some other food that is going to spike your blood sugar. You're going to be on this roller coaster, and your emotional state [and] well-being is going to be on that roller coaster as well.

So, we want to level that out because mental health is not just in your head, it's in your nutrition as well. It's in the small things that we do day-to-day, and our small choices add up, and...you really need to fuel up, because you've got important work to do. You’ve got to take care of your clients. You’ve got to take care of each other, and most importantly, you've got to take care of yourself. So, join me next week for another Wellness Tip of the Week.

Aaron Shaw, OTR/L, CHT, CSCS, dives into the science of this sensation and offers advice on how to prevent it.

Wellness Tip of the Week: Avoiding the "hangry" feeling

MSD Animal Health, a division of Merck & Co, Inc, announced that it has received FDA approval for its gentamicin, posaconazole, and mometasone furoate otic suspension (Mometamax Single; Merck). This latest addition to Merck’s portfolio is a new, convenient single-dose product for canine patients with otitis externa and will be available in veterinary clinics across the United States in summer 2025.

“Every case of otitis externa is unique, and having a range of treatment options allows veterinarians to tailor care to each individual dog. Mometamax Single offers a convenient, in-clinic solution that expands our otic portfolio and supports our commitment to delivering flexible, effective treatment options,” said Christine McKinney, DVM, DACVD, small animal dermatology specialist, veterinary insights and medical affairs, MSD Animal Health.

“Therefore, Mometamax Single as a new option also alleviates stress for pet owners because veterinarians can administer a single dose in [the] clinic and ensure a safe, effective, and complete treatment regimen,” she continued.

Canine patients with otitis externa suffer from redness, swelling, and pain, with symptoms also including odor, constant head shaking, and discharge. It is currently one of the most commonly treated conditions within veterinary medicine, and if it is left untreated, patients can develop chronic pain, hearing loss, and recurrent infections. 

According to the release, this new product is indicated to treat otitis externa associated with susceptible strains of yeast (

) in canine patients. It has 3 active ingredients—gentamicin, posaconazole, and mometasone furoate—and is the only FDA-approved, 1-dose, in-clinic product that is labeled to treat

“Mometamax Single represents our newest innovation in the otitis space, and we are proud to deliver this differentiated product that provides an effective treatment for dogs and peace of mind to pet owners,” said Alison De Leon, VMD, director, global pharmaceutical development, MSD Animal Health.

“Daily treatment can be a challenge for busy pet parents, especially when their dog is suffering from a painful condition like otitis. In such cases, Mometamax Single offers an effective, convenient alternative. By expanding our otic portfolio, we’re giving veterinarians greater flexibility to choose the right treatment path for each individual case, whether that’s daily at-home care or a 1-time in-clinic approach,” she concluded. 

This product is to be used in only canine patients and should be administered by a veterinary professional. Mometamax Single is also not to be used in dogs with known tympanic membrane perforation or with known or suspected hypersensitivity to gentamicin, posaconazole, or mometasone furoate. MSD Animal Health is instructing professionals to refer to the product label for full safety. 

Epidemiological study of dogs with otitis externa in Cape Breton, Nova Scotia. News release. MSD Animal Health. May 2, 2025. Accessed May 8, 2025. https://www.msd-animal-health.com/2025/05/02/fda-approves-mometamax-single-to-treat-otitis-externa-in-dogs/

The latest canine otitis externa medication is the only FDA-approved, 1-dose, in-clinic treatment for Pseudomonas aeruginosa and other pathogens.

FDA approves Mometamax Single

Jb Minter, DVM, MS, DACZM, discusses systemic analgesic, opioid, NSAID, and local anesthetic use in amphibians

Anesthetic and analgesic options for amphibians 

Although the field of pain management in amphibians is still in development, there are still key factors veterinary professionals should know. Jb Minter, DVM, MS, DACZM, director of animal health and chief veterinarian at the North Carolina Zoo in Asheboro, talks about the options available for managing pain in amphibians, as part of a discussion on his Fetch dvm360 Conference lecture, “Navigating Amphibian Anesthesia and Analgesia,” which is now available on-demand for CE credit. In the video, Minter emphasizes that local anesthetics, such as lidocaine and bupivacaine, must be used cautiously in amphibians to avoid toxicity, which can be fatal to these animals.

Below is the interview transcript, lightly edited for clarity:

 We're going to talk quite a bit about this during the presentation, but pain management is still a well-evolving area. There's a lot that we still do not know. There are so many different species of amphibians out there. What we do know about one particular species may not work for another one.

There are some options—systemic analgesics, NSAIDS [nonsteroidal anti-inflammatory drugs]. People have used meloxicam, ketoprofen, parecoxib, [and] flunixin for amphibians. But their safety and all their efficacy in all these different species has...only been studied in a few different species, so it's all over the place.

You can use opioids...with most of the exotic species that people may be dealing with on a day-to-day basis. They do have the opioid receptors, but which one works, at what time, [and] how long it stays with them [is] still being explored in our amphibian patients. But we've used morphine; it’s a pretty common one. We've used that for a lot of amphibians that have needed some type of analgesics.

You can also use local anesthetics such as lidocaine and bupivacaine, but you have to be cautious because those particular drugs [have] some toxic effects, and you can easily kill an amphibian if you use too much of those local anesthetics.

delivers expert-led veterinary continuing education on your schedule. With

, you can access top-tier sessions anytime, anywhere—whether at home, in the clinic, or on the go. Ready to earn CE credits? Watch this session and more on

Jb Minter, DVM, MS, DACZM, discusses systemic analgesic, opioid, NSAID, and local anesthetic use in amphibians.

A team of experts from Texas A&M University and the University of Georgia are collaborating on a series of research projects.

Chagas disease is being studied by a team of investigators from Texas A&M University in College Station and the University of Georgia (UGA) in Athens. The collaborative team has several new projects that aim to address prevalence, diagnostics, and treatment for the benefit of canines and humans. This work is supported by more than $4 million in funding from the federal government and nongovernmental organizations, according to Texas A&M.

Chagas disease is a tropical condition that is common in dogs and humans and is caused by the 

 parasite. The disease is most commonly spread by fecal matter from triatomine insects, which are also known as "kissing bugs" that have bitten and fed on the blood of infected hosts.

Chagas disease can be life-threatening to both canines and humans when left untreated.

 Often unnoticed in early stages, the disease is a chronic infection that can lead to serious heart and digestive system problems. Early diagnosis is important, as the infection is difficult to detect and the disease is challenging to treat, according to Texas A&M.

“These projects will advance Chagas disease research to understand the process of natural infections, disease, and effect of treatments,” Sarah Hamer, DVM, PhD, MS, DACVPM, a project leader and professor in the Texas A&M College of Veterinary Medicine and Biological Sciences (VMBS), said in a news release.

 “These projects combine many aspects of biomedical research. We’re conducting field and laboratory research, treating dogs, measuring clinical outcomes, and studying ecological factors. It’s truly a ‘One Health’ approach.”

Most human cases of Chagas disease have been reported from South and Central America and Mexico, but there are also established triatomine bug populations across the southern United States, according to Texas A&M. Dogs in Texas are important data sources for Chagas disease because they often encounter these parasites, according to investigators.

“Unfortunately, Texas has emerged as a hot spot of infected kissing bugs, infected wildlife, and infected dogs across the landscape,” Hamer said.

 “We think dogs are getting infected when they eat the insects.”

Study shows that Mexican free-tailed bats do not carry the parasite responsible for Chagas disease

Participants in the study include privately owned canines and working dogs. “Dogs that work in customs and border protection and for the Transportation Security Administration can be exposed to Chagas disease,” Ashley Saunders, DVM, DACVIM, a project leader, professor, and cardiologist in the Department of Small Animal Clinical Studies at Texas A&M VMBS, said in the release. “Some of our work will be a continuation of previous studies of the clinical impacts of the disease on canine cardiac health, as well as how the dogs are exposed to the parasite so we can help minimize their risk.”

While announcing the study initiative and funding, Texas A&M addressed 3 investigation projects included in the research initiative. They include one that may help advance human health through the study of canine patients, another that focuses on working dogs, and a third aiming to improve the management of Chagas disease in canines.

In the first project, funded by the National Institutes of Health, investigators aim to establish optimal protocols for the detection and treatment of the Chagas infection that can potentially lead to the prevention of cardiac disease development. Innovative diagnostics and treatment strategies are being utilized to conduct this study.

"There are a number of important questions related to treatment efficacy and the protection that cured subjects have from future infection that cannot be easily addressed in humans but can be in these dog populations that are under intense transmission pressure in Texas,” Rick Tarleton, PhD, a project leader, UGA Regents Professor, and UGA Athletic Association Distinguished Professor, said in a news release.

This study will track infected individuals using a combination approach with sensitive tests that detect parasite DNA and the body’s response to infection.

Dogs are a good model for examining the effectiveness of the treatment for humans, as Chagas disease presents similarly in canines as it does in humans. The drug being administered in the study is an existing treatment for Chagas disease in humans, according to Saunders.

Investigators will monitor working dogs owned by the US Department of Homeland Security (DHS) in the second project, which is funded by the DHS. These dogs are often trained in areas where Chagas disease is prevalent, including Texas, and investigators are seeking to understand how they are exposed to the disease and the effects it can have on heart health.

“One of the reasons that monitoring dogs is so helpful is because Chagas disease can produce so many different subsets of health problems,” Saunders said in the release.

 “Some dogs end up with a heart abnormality, but a large number continue living and working happily for many years. Others will die quite suddenly, before anyone knew they had the disease.”

“Recording health information from such a large population of dogs will hopefully help us understand why the disease develops in different ways,” Hamer added.

Investigators noted that although government-working dogs are commonly trained in Texas, they can perform their jobs anywhere in the US. Therefore, working dogs infected with 

could be transported to regions across the country that do not currently have as much prevalence or awareness of the parasite.

The third project is supported by the American Kennel Club Canine Health Foundation. It will develop a staging system for Chagas disease in dogs, with the investigative team treating and monitoring pet dogs brought to Texas A&M’s Small Animal Teaching Hospital.

“The staging system we develop will help us to categorize the severity of disease, making it easier to determine which dogs will benefit most from drug treatment,” Saunders said.

“This scoring system will work hand-in-hand with our improved diagnostic and treatment plan.”

Research collaboration takes ‘One Health’ approach to study Chagas disease exposure, treatment effectiveness. News release. Texas A&M University College of Veterinary Medicine and Biological Sciences. May 7, 2025. Accessed May 7, 2025. 

https://stories.tamu.edu/news/2025/05/07/research-collaboration-takes-one-health-approach-to-study-chagas-disease-exposure-treatment-effectiveness/

Chagas disease in dogs. Texas A&M College of Veterinary Medicine and Biological Sciences. April 5, 2018. Accessed May 7, 2025. 

https://vetmed.tamu.edu/news/pet-talk/chagas-disease-in-dogs-2018/

About Chagas disease. CDC. September 4, 2025. Accessed May 7, 2025. 

https://www.cdc.gov/chagas/about/index.html#:~:text=About%208%20million%20people%20globally,where%20we%20find%20Chagas%20disease